MDNA.F Stock Overview An immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Medicenna Therapeutics Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Medicenna Therapeutics Historical stock prices Current Share Price CA$1.18 52 Week High CA$2.20 52 Week Low CA$0.29 Beta 1.11 1 Month Change 4.52% 3 Month Change -20.27% 1 Year Change 284.86% 3 Year Change -33.33% 5 Year Change -54.45% Change since IPO -21.12%
Recent News & Updates
Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium Dec 14
Medicenna Therapeutics Corp Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA®? (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study Dec 05
Medicenna Therapeutics Corp. Announces Updated Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference Nov 27
Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) Nov 26
Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC Nov 12
Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Nov 08 See more updates
Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium Dec 14
Medicenna Therapeutics Corp Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA®? (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study Dec 05
Medicenna Therapeutics Corp. Announces Updated Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference Nov 27
Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) Nov 26
Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC Nov 12
Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Nov 08
Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference Sep 11
Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors Aug 15
Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024 Jul 22
Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe Jun 26
Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024 Jun 05
Medicenna Therapeutics Files Form 15 May 15 Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P. May 01
Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P. Apr 27
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study Apr 10
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting Mar 06
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors Feb 13
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab Jan 09
Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp Nov 18
Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting Nov 10
Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer Nov 07
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Nov 04 Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index Nov 03
Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer
New major risk - Revenue and earnings growth Oct 27 Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY
Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer Oct 11
Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy Oct 05
Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy Sep 29
Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer Aug 29 Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer
Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study Aug 10
Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee Aug 09
Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023 Jul 15
Price target decreased by 8.9% to US$5.83 Jun 21
Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023 Jan 27
High number of new and inexperienced directors Nov 16
Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting Nov 12
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Oct 29
Lead Independent Director recently bought US$54k worth of stock Oct 12
Medicenna extends period to exercise certain warrants Sep 30
Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study Sep 29
Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022 Sep 24
Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial Sep 14
Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment Sep 13
Price target decreased to US$7.00 Aug 16
Medicenna Therapeutics GAAP EPS of -$0.07 in-line Aug 15 Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million. Aug 11
Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million. Aug 10
Medicenna Therapeutics stock slides on launch of units offering Aug 08
Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022 Aug 06
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study Jul 28
Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022 Jul 09
No longer forecast to breakeven Jun 28
Price target decreased to US$8.40 Jun 23
Price target increased to US$10.50 Jun 13
Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022 Jun 09
Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022 Jun 08
Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting May 12
Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study May 04
High number of new and inexperienced directors Apr 27 Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting
Forecast to breakeven in 2025 Apr 01
Price target decreased to US$9.20 Mar 15
Medicenna Therapeutics Corp. Announces Management Changes Mar 05
High number of new and inexperienced directors Feb 05
High number of new and inexperienced directors Feb 05
Medicenna Therapeutics Corp. to Report Q3, 2022 Results on Feb 09, 2022 Feb 03
Medicenna Therapeutics Corp. Announces Board Appointments Feb 01
Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer Jan 27
Medicenna Therapeutics Corp. Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with Mdna11 Treatment in the Phase 1/2 Ability Study Dec 23
Medicenna Therapeutics Corp. Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada Dec 18
Founder recently bought US$85k worth of stock Nov 11
Medicenna Therapeutics Corp. Doses First Patient in MDNA11 Phase 1/2 Ability Study Sep 15
Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating Its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer Jul 15
Medicenna Therapeutics Corp. Announces Submission of Clinical Trial Application in Australia for A Phase 1/2 Study of Mdna11 Jun 25
Medicenna Therapeutics reports FY results May 28
Medicenna Therapeutics Corp. Announces Peer-Reviewed Publication of Clinical Data from Phase 2B Trial Evaluating Mdna55 in Recurrent Glioblastoma May 08
Medicenna posts positive data from mid-stage brain cancer study May 07
New 90-day low: US$3.68 Mar 05
Medicenna announces ATM sales facility for $25M Dec 31
New 90-day high: US$5.97 Dec 29
Medicenna Therapeutics Corp. Provides Update on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme At Key Opinion Leader Call Dec 03
Medicenna Announces Upcoming Oral Presentations At the 2020 Society for Neuro-Oncology Annual Meeting Nov 19
Medicenna Therapeutics reports Q2 results Nov 13
Medicenna Therapeutics Corp. Presents Late Breaking Abstract Updating Results from Phase 2B Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting Oct 27 Shareholder Returns MDNA.F US Biotechs US Market 7D -5.6% -3.6% -2.4% 1Y 284.9% -2.6% 23.4%
See full shareholder returns
Return vs Industry: MDNA.F exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: MDNA.F exceeded the US Market which returned 23.4% over the past year.
Price Volatility Is MDNA.F's price volatile compared to industry and market? MDNA.F volatility MDNA.F Average Weekly Movement 13.0% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: MDNA.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MDNA.F's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors.
Show more Medicenna Therapeutics Corp. Fundamentals Summary How do Medicenna Therapeutics's earnings and revenue compare to its market cap? MDNA.F fundamental statistics Market cap US$93.00m Earnings (TTM ) -US$18.57m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MDNA.F income statement (TTM ) Revenue CA$0 Cost of Revenue CA$0 Gross Profit CA$0 Other Expenses CA$26.68m Earnings -CA$26.68m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 08:46 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Medicenna Therapeutics Corp. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Charles Zhu Guggenheim Securities, LLC Swayampakula Ramakanth H.C. Wainwright & Co. Catherine Novack JonesTrading Institutional Services, LLC
Show 1 more analysts 
